Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InxMed of Shanghai Doses First Patient in US Trial of FAK Inhibitor

publication date: Mar 17, 2020

InxMed (Shanghai) Co. has dosed the first patient in a Phase Ib trial of its focal adhesion kinase (FAK) inhibitor in melanoma patients. The trial will conducted in Australia and the US in patients with metastatic uveal melanoma or NRAS mutant metastatic melanoma. IN10018 will be tested as a monotherapy and in combination with Roche's MEK inhibitor Cotellic™ (cobimetinib), which was approved to treat melanoma in 2015. Previously, InxMed was approved to start a China Phase I trial of IN10018 in patients with advanced or metastatic gastric cancer. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here